文献速递乳腺癌放疗放疗物理与技术

乳腺癌放疗分割方案的使用差异:生存结局与成本影响

Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications.
PubMed 文献 · Radiother Oncol · 2020-07-25

该研究基于澳大利亚新南威尔士州2009-2013年接受乳腺癌放疗的10,482例患者队列,分析大分割放疗的使用差异、生存结局及成本影响。多因素分析显示年龄增长、右侧、2013年治疗、早期 stage、较低社会经济地位和区域居住是大分割的独立预测因素;5年生存无差异。

要点

  • 大分割放疗在乳腺癌中未被充分使用,存在实践差异。
  • 年龄增长、右侧、2013年治疗、早期stage、较低社会经济地位和区域居住预测大分割使用。
  • 5年生存在各分割方案间无差异,循证实践可降低治疗成本。

核心结论

  • 大分割放疗在新南威尔士州乳腺癌放疗中 appears 未被充分使用。
  • 循证实践将转化为降低的医疗治疗成本。

研究设计与样本

  • 基于人群的队列研究,纳入2009-2013年新南威尔士州中央癌症登记处记录的接受乳腺癌放疗的患者。
  • 共10,482例患者纳入分析,分为3个队列:单纯乳腺7000例、乳腺+淋巴结1119例、全胸壁2363例。
  • 使用逻辑回归模型识别与分割类型相关的因素,多变量Cox比例风险模型估计生存结局,并估算每疗程成本及循证分割相关的潜在节省。

主要发现

  • 多变量分析中,年龄增长、右侧、2013年治疗、早期stage、较低社会经济地位和区域居住是单纯乳腺放疗中大分割的独立预测因素。
  • 在乳腺+淋巴结和胸壁队列中,预测大分割使用的共同因素是年龄增长。
  • 多变量生存分析显示,5年时各分割方案间无差异。

临床怎么用

  • 临床应关注大分割放疗在乳腺癌中的循证应用,减少不必要的实践差异。
  • 在符合条件患者中采用循证分割方案可能降低医疗成本而不影响5年生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Substantial variation in the adoption of hypofractionation for breast radiation therapy has been observed, despite the availability of consensus guidelines. This study aimed to investigate the variation in radiation therapy fractionation in breast cancer patients in New South Wales (NSW), Australia, and to estimate survival outcome and cost implications. MATERIALS AND METHODS: This is a population-based cohort of patients who received radiation therapy for breast cancer (2009-2013), as captured in the NSW Central Cancer Registry. A logistic regression model was used to identify factors associated with fractionation type. Survival outcome was estimated using multivariable Cox proportional hazards model. Cost per treatment and potential cost saving associated with evidence-based fractionation was estimated. RESULTS: A total of 10,482 patients were available for analysis, divided into 3 cohorts (breast alone: N = 7000; breast + nodes: N = 1119; all chestwall: N = 2363). In multivariable analysis, increasing age, laterality (right), year of treatment (2013), early stage, lower socioeconomic status, and regional area of residence were independent predictors of hypofractionation for breast alone radiation therapy. For the breast + nodes and chest wall cohorts, common factors that predicted the use of hypofractionation were increasing age. In multivariable survival analysis, there was no difference between the fractionation regimens at 5 years. Estimated radiation therapy cost of this cohort approximated $52.1 million, compared with $38.5 million had these patients been treated with evidence-based fractionation. This demonstrated a potential saving of $13.6 million. CONCLUSION: Hypofractionation appears underused for breast radiation therapy in NSW over time. This study highlights that evidence-based practice will translate to reduced health care treatment costs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Batumalai V, Delaney GP, Descallar J, et al. Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications. Radiother Oncol. 2020. PMID: 32721419. doi:10.1016/j.radonc.2020.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。